Cytokeratin 17 Antibody / CK17 Antibody

Cytokeratin 17 Antibody Overview

Cytokeratin 17 Antibody reagents target keratin 17 (KRT17), a type I intermediate filament protein expressed in basal epithelial cells of skin appendages, hair follicles, and certain mucosal tissues. KRT17 plays a critical role in structural support, wound healing, and cell signaling, often co-expressed with keratin 6 during epithelial repair and hyperproliferation.

KRT17 is clinically significant due to its expression in basal cell carcinomas, squamous cell carcinomas, and other epithelial tumors. It is also upregulated in inflammatory skin conditions such as psoriasis. Because of these roles, the Cytokeratin 17 Antibody is a valuable tool in dermatology, oncology, and developmental biology. The CK17 Antibody further supports applications in diagnostic pathology, regenerative medicine, and translational research.

Why Choose Cytokeratin 17 Antibodies from NSJ Bioreagents?

NSJ Bioreagents supplies Cytokeratin 17 Antibodies validated for immunohistochemistry, immunofluorescence, western blotting, ELISA, and flow cytometry. Each Cytokeratin 17 Antibody undergoes stringent quality control to ensure specificity, reproducibility, and minimal cross-reactivity.

By selecting Cytokeratin 17 Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and performance. Our antibodies provide reliable staining in epithelial tissues, consistent protein detection in lysates, and robust results across platforms. Detailed datasheets, suggested controls, and validated protocols further support reproducibility in both research and clinical applications.

Applications of Cytokeratin 17 Antibodies

The Cytokeratin 17 Antibody supports diverse applications in epithelial biology and disease research.

1) Dermatology and Skin Biology

• Cytokeratin 17 Antibodies highlight expression in basal keratinocytes and hair follicles.

• The Cytokeratin 17 Antibody tracks keratinocyte activation during wound repair.

• CK17 Antibody reagents clarify structural roles in skin appendage biology.

2) Inflammatory Skin Disorders

• Cytokeratin 17 Antibodies are used to study psoriasis and other hyperproliferative conditions.

• The Cytokeratin 17 Antibody supports research into keratinocyte-driven inflammation.

• CK17 Antibody reagents provide biomarkers for skin pathology.

3) Oncology and Tumor Biology

• Cytokeratin 17 Antibodies detect expression in basal cell carcinomas and squamous cell carcinomas.

• The Cytokeratin 17 Antibody supports tumor classification in pathology workflows.

• CK17 Antibody reagents help validate biomarkers in oncology research.

4) Pathology and Diagnostics

• Cytokeratin 17 Antibodies confirm basal epithelial lineage in diagnostic panels.

• The Cytokeratin 17 Antibody provides clarity in distinguishing epithelial from non-epithelial tumors.

• CK17 Antibody tools are integrated into clinical immunohistochemistry.

5) Developmental and Stem Cell Biology

• Cytokeratin 17 Antibodies track epithelial lineage specification in embryogenesis.

• The Cytokeratin 17 Antibody validates keratin expression in stem cell-derived organoids.

• CK17 Antibody reagents support regenerative medicine focused on skin and mucosal tissues.

6) Translational and Clinical Research

• Cytokeratin 17 Antibodies are applied in biomarker-driven oncology and dermatology trials.

• The Cytokeratin 17 Antibody contributes to patient stratification in precision medicine.

• CK17 Antibody reagents provide reproducibility across translational workflows.

Why Are Cytokeratin 17 Antibodies Important?

KRT17 plays critical roles in epithelial resilience, repair, and pathology. The Cytokeratin 17 Antibody enables precise detection of this protein, while the CK17 Antibody complements broader diagnostic and translational applications.

In dermatology, Cytokeratin 17 Antibodies reveal keratinocyte activation during wound healing and inflammatory disorders. In oncology, the Cytokeratin 17 Antibody supports classification of carcinomas and identification of tumor aggressiveness. In developmental biology, CK17 Antibody reagents validate epithelial differentiation and lineage commitment.

Clinically, KRT17 expression serves as a biomarker for skin tumors and inflammatory diseases. Cytokeratin 17 Antibodies provide reproducibility and diagnostic confidence, linking laboratory findings with patient care.

Conclusion

Cytokeratin 17 is an essential epithelial marker with roles in wound healing, inflammation, and cancer. The Cytokeratin 17 Antibody equips scientists and clinicians with validated reagents for detecting KRT17 in dermatology, oncology, and pathology, while the CK17 Antibody provides complementary support in translational medicine. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing epithelial biology and improving diagnostic outcomes.